Small molecules

By Dr Natalia Dadivanyan, Segment Marketing Manager, Malvern Panalytical  Small molecules can face big challenges  Despite the emergence of, and excitement around, advanced therapeutic modalities, traditional small molecule pharmaceuticals still occupy a significant and steadily growing share of the market. A recent report indicated the current market size to be ~$166 billion, and a 5% compound […]

A new system utilising artificial intelligence (AI), ‘building-block’ chemistry and a molecule-making machine could speed up innovation and drug discovery, as well as make complex chemistry automated and accessible. Researchers at the University of Illinois Urbana-Champaign and collaborators in Poland and Canada doubled the average yield of a special, hard-to-optimise type of reaction linking carbon […]

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases.   The agreement will see the companies combining their expertise and capabilities in neuroscience to discover and develop small molecules that modulate G protein-coupled receptor (GPCR) targets that are associated with neurological […]

Two life sciences companies have been awarded an €800K grant for their work developing a small molecule therapy for a fast-growing blood cancer.  Lead Pharma and Oxeltis were awarded the funding from EUREKA Eurostars for their three-year EPIGENEXT joint project.   Through the project, Lead Pharma and Oxeltis aim to develop a first-in-class small molecule therapy […]

Developer of software for drug discovery Optibrium has expanded its UK headquarters by moving to a larger space of Cambridge Innovation Park North.   Located in one of the UK’s leading technology hub, Optibrium’s new headquarters will provide new offices, meeting rooms, social areas and on-site leisure activities to promote employee well-being. The premises will facilitate […]

Artificial intelligence (AI) company X-Chem has announced that its drug discovery platform XD3 is now available to biopharma partners and clients. XD3 is the company’s small molecule drug discovery platform and combines data generated through DNA-encoded library (DEL) screening, along with analytical and predictive capabilities offered by A-Chem’s AI platform, Artemis AI. The end-to-end platform […]

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. […]

OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes.  The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. The programmes include:  MC2 (melanocortin-2), a GPCR that binds to […]

Mount Sinai researchers have developed a therapy that shows promise against a fatal paediatric leukaemia. The small-molecule therapy was highly effective in fighting a type of acute myeloid leukaemia in both in vitro and in vivo experiments, according to research published in Science Translational Medicine in September 2021. The therapy, named MS67, causes the degradation of the WDR5 protein, […]

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals to vitamins, hormones and drugs […]